Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00811018 · ClinicalTrials.gov registry record · Phase 3
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,192
- Enrollment target
NCT00811018: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00811018 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1,192 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00811018, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,192 participants
- Enrollment target
Study Summary
This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the study is closed.
Primary Outcome
All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product were reported.
Interventions
- DRUG Sitaxsentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,192 participants |
| Start Date | 2003-03 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Why NCT00811018 stopped before completion
NCT00811018 is an interventional study that assigns participants to a tested intervention. Its 1,192 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% higher).
The record links to 0 conditions, and to 1 intervention - of which Sitaxsentan is the first listed.
NCT00811018 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00811018 about?
NCT00811018 is a clinical study titled "A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension". This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the study is closed.
What is the current status of trial NCT00811018?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,192 participants. The study started on 2003-03. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00811018?
The interventions under investigation include: Sitaxsentan (DRUG).
Who is sponsoring clinical trial NCT00811018?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00811018's enrollment target sits among peer trials
1,192 229th of 2000 higher than 1,772 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07177339 · 1,196 participants · Phase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
- NCT06290869 · 1,188 participants · Phase 3
Tobacco Education and Lung Health Study (TEAL)
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia